
AVXL Stock Forecast & Price Target
AVXL Analyst Ratings
Bulls say
Anavex Life Sciences is poised for success as it works to strengthen its regulatory positioning and further develop its promising treatments for a variety of CNS disorders with high unmet need, including Alzheimer's disease, Parkinson's disease, and Rett syndrome. With additional clinical and biomarker data to address feedback from regulatory agencies and ongoing engagement with the FDA, the company is taking a strategic and disciplined approach to its development strategy. While the recent withdrawal in the EU introduces timing uncertainty, the company maintains its focus on advancing its treatments and has been encouraged by the EMA's SME Office. Our valuation reflects the potential of ANAVEX 2-73, with a $24.0 price target derived from a 30% discount rate and adjusted probabilities of success in the US and EU markets.
Bears say
Anavex Life Sciences is in the process of discussing with regulators to define a viable US regulatory pathway for their treatment in Alzheimer's disease, while also highlighting potential neuroprotective benefits of their drug in preserving brain volume according to recent data. This progress indicates a potential for future growth and improvement, although further studies and regulatory approvals are still necessary.
This aggregate rating is based on analysts' research of Anavex Life Sciences and is not a guaranteed prediction by Public.com or investment advice.
AVXL Analyst Forecast & Price Prediction
Start investing in AVXL
Order type
Buy in
Order amount
Est. shares
0 shares